A Randomised, Double-Blind, in Parallel Groups Placebo-Controlled, Mono-Centre, Phase I Study to Assess After Allergen Challenge in an Allergen Exposition Chamber the Effect and Its Time Course of Sublingual Immunotherapy (SLIT) Administered as 300IR Allergen-Based Tablets Once Daily to Adults Suffering From Grass Pollen Rhinoconjunctivitis.

Trial Profile

A Randomised, Double-Blind, in Parallel Groups Placebo-Controlled, Mono-Centre, Phase I Study to Assess After Allergen Challenge in an Allergen Exposition Chamber the Effect and Its Time Course of Sublingual Immunotherapy (SLIT) Administered as 300IR Allergen-Based Tablets Once Daily to Adults Suffering From Grass Pollen Rhinoconjunctivitis.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 14 Oct 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Results were published in the Journal of Allergy and Clinical Immunology.
    • 17 Mar 2009 Results were reported at the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top